DESIGNER INSULINS IN GESTATIONAL DIABETES DR.T.RAMANI DEVI MD DGO FICS FICOG RAMAKRISHNA NURSING HOME TRICHY.
GESTATIONAL DIABETES MELLITUS - CURRENT CONCEPTS Dr.Vivek Sundaram.MD.DNB.MRCP(UK) Consultant – Internal Medicine,Diabetes & Critical Care Sundaram Hospital,Trichy.
Anil Kapur. Women and Diabetes 123.8 192.3 155.6 233.5.
Atherogenic Diabetic Dyslipidemia (ADD) - Time to Relook & Evaluate Treatment Options.
Celphos poisoning
Newer Iron Preparation
Bibliography and Appendices
Raising awareness at the grassroots level – community and workplace This slideset was developed in 2007 with support from GlaxoSmithKline.
PREVALENCE OF NAFLD IN DIABETIC PATIENTS The world-wide prevalence of non-alcoholic fatty liver disease (NAFLD) is: o Western countries: 15% to 40%
A therogenic D iabetic D yslipidemia ( ADD ) - Time to Relook & Evaluate Treatment Options
WHAT IS DRIVING THE DIABETES EPIDEMIC IN INDIA? WHAT IS DRIVING THE DIABETES EPIDEMIC IN INDIA? MADRAS DIABETES RESEARCH FOUNDATION, Gopalapuram, Chennai.
prof_nk_ganguly_-_ndm1
